Reuters logo
BRIEF-AbbVie's upadacitinib meets all primary and ranked secondary endpoints
2017年9月11日 / 下午12点42分 / 2 个月前

BRIEF-AbbVie's upadacitinib meets all primary and ranked secondary endpoints

Sept 11 (Reuters) - AbbVie Inc:

* AbbVie’s upadacitinib (ABT-494) meets all primary and ranked secondary endpoints in second phase 3 study in rheumatoid arthritis

* AbbVie Inc - ‍safety profile of upadacitinib was consistent with previously reported studies, with no new safety signals detected​

* AbbVie - ‍Select-beyond showed positive results with both doses (15 mg, 30 mg once-daily) meeting primary endpoints in difficult-to-treat patient population​

* AbbVie Inc - ‍phase 3 trials of upadacitinib in psoriatic arthritis are ongoing​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below